U.S. Stock Insider Trading | Palisade Bio Discloses Two Insider Transactions on February 13

K-LinePoet · 2026-03-16T19:26:18+00:00

On February 13, 2026, Palisade Bio disclosed insider trading activity by executives and directors. Finley John David sold 3896 shares, and Jones Mitchell Lawrence sold 1989 shares. The company focuses on biopharmaceutical research and development for central nervous system diseases and holds multiple stem cell technology patents.

K-LinePoet

2026-03-16 19:26:18

Abstract generation in progress

On February 13, 2026, Palisade Bio (PALI) disclosed two insider trading transactions. Director Finley John David sold 3,896 shares on February 12, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 13, 2026	Executive	Jones Mitchell Lawrence	February 12, 2026	Sell	1,989	1.75	3,480.75
February 13, 2026	Director	Finley John David	February 12, 2026	Sell	3,896	1.75	6,818.00
January 21, 2026	Director	Williams Donald Allen	January 16, 2026	Buy	5,000	1.67	8,356.00
January 13, 2026	Director	Williams Donald Allen	January 9, 2026	Buy	5,000	1.88	9,400.00
May 30, 2024	Executive	Jones Mitchell Lawrence	May 28, 2024	Sell	1,271	4.76	6,049.96
May 30, 2024	Director	Finley John David	May 28, 2024	Sell	2,033	4.76	9,677.08
May 29, 2024	Director	Williams Donald Allen	May 28, 2024	Buy	1,000	4.86	4,863.00
May 28, 2024	Director	Finley John David	May 24, 2024	Buy	1,000	4.81	4,810.00
May 22, 2024	Director	Finley John David	May 20, 2024	Buy	666	4.97	3,311.69
May 8, 2024	Executive	Jones Mitchell Lawrence	May 6, 2024	Sell	137	8.46	1,159.02

[Company Information]

Palisade Bio, Inc., founded in 1997, is a biopharmaceutical company dedicated to developing treatments for central nervous system diseases using its proprietary human neural stem cell technology. The company aims to commercialize this technology as a tool for discovering next-generation small molecule drugs and to create a biological cell therapy for CNS disorders. Currently, the company has laboratories and offices in Rockville, Maryland, with additional research facilities in San Diego and China. Neuralstem, Inc. has developed and maintains a series of patents and patent applications that form the proprietary basis of its R&D efforts. The company owns or exclusively licenses 30 U.S. and foreign patents and 42 U.S. and foreign patent applications related to its stem cell technology and small molecule compounds.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.